Determination of methylmalonic acid (MMA) in serum has been established as an accurate test for the diagnosis of cobalamin deficiency. We describe here the development and performance of a liquid-chromatographic assay of MMA in blood and urine. The assay is based on our recent finding that one of the carboxylic acid moieties of some short-chain dicarboxylic acids reacts with the fluorogenic reagent 1-pyrenyldiazomethane in an aqueous medium, whereas the other remains underivatized (Anal Chem 1992;63:31 5-9). The pH-dependent ionization of the free carboxylic acid group of 1-pyrenylmethyl monoesters permits retention on anion-exchange columns, which are used for solid-phase extraction. The analysis is done with a cyanopropyl column coupled in series with an octade- One assay involves acidification, extraction with ether, drying of sample, purification by HPLC, a second extraction step, and another drying before derivatization and GC-MS (7). In another serum assay, the samples are cleaned up by solid-phase extraction before derivatization and CC-MS (10). A CC-MS assay with only one extraction step has a lower limit of detection of 0.5 mol/L (11), which is not sufficient for determining serum MMA in healthy humans.
One assay involves acidification, extraction with ether, drying of sample, purification by HPLC, a second extraction step, and another drying before derivatization and GC-MS (7) . In another serum assay, the samples are cleaned up by solid-phase extraction before derivatization and CC-MS (10). A CC-MS assay with only one extraction step has a lower limit of detection of 0.5 mol/L (11), which is not sufficient for determining serum MMA in healthy humans.
We here describe the construction and performance of the first liquid-chromatographic method for MMA in serum, which also works for plasma anticoagulated with EDTA or heparin, and for urine. The assay is based on the fact that only one carboxylic moiety of MMA reacts with 1-pyrenyldiazomethane (PDAM). The unique product carries one free carboxylic acid group (17), and the ionization of this group is exploited in separation of the product by a procedure involving solid-phase extraction on ion-exchange columns followed by HPLC. Both steps are carried out with an automated sample processor. CT). The ODS column was mounted in a column heater (Model SP 8792; Spectra Physics, San Jose, CA). The fluorescence of the column effluent was monitored by a Shimadzu RF-535 fluorescence detector (Kyoto, Japan). The wavelength of the primary light path was routinely adjusted to 340 nm and the fluorescent emission was recorded at 376 nm with a Model SP 4290 integrator (Spectra Physics).
Materials and Methods

Materials
Procedures
Sample collection and storage. Blood was collected into evacuated tubes and allowed to clot at room temperature for 30 mm before the serum fraction was transferred to an empty glass vial. Heparin-plasma and EDTA-plasma were obtained by collecting blood into Vacutainer Tubes (Becton Dickinson, Meylan Cedex, France) containing the respective anticoagulants. The final concentration of EDTA in the plasma phase was 4 mmolIL. Plasma was separated from the formed elements of blood within 10 mm by centrifugation. Serum, plasma, and urine were stored at -20 #{176}C until analysis. Samples (20 4,) were injected into the CN column, which was coupled in series with the ODS column. Both columns were equilibrated with 40% A, 54% B, and 6% C, and were developed with a small linear gradient of tetrahydrofuran, obtained by changing the composition of the mobile phase to 40% A, 51% B, and 9% C at 22 mi. At this time, a second linear gradient was started, to end at 0% A, 50% B, 0% C, and 50% D at 45 mm. From 45 miii on, both columns were washed with 40% A and 60%Bfor5min.TheflowratewaslmL/minandthe column temperature of the CN column was 25#{176}C; the ODS column was heated to 50#{176}C. The pressure range was 20-35 kPa during a chromatographic run. To serum containing endogenous MMA at 0.12 pmoJJL we added 0.5, 5, and 50 pmol of MMA per liter. To determine the within-run precision, we assayed 10 replicates of each serum sample in a single run. The betweenrun precision was determined by analyzing the same serum samples on 10 different days within 3 weeks.
Analytical recovery in serum and urine was assessed by adding different amounts of MMA to serum or urine from healthy subjects. Urine was diluted with borate buffer (see Sample processing) before MMA was added. Samples were assayed in 10 replicates, and the results were expressed as the percentage of the values obtained by adding the same amounts of MMA to borate buffer.
Other assays. Total plasma homocysteine was determined by a modification (19) of a fully automated assay described previously (20). Serum cobalamin was determined with a microparticle enzyme assay performed with an IMx system from Abbott (Abbott Park, IL).
Resufts
Assay Performance
Sample processing and derivatization.
We deproteinized serum/plasma by mixing one volume of sample (usually 100 pL) with three volumes of methanol/acetonitrile. This ensured efficient protein precipitation at 0#{176}C within 30 min. Methanol was present to prevent phase separation after the addition of ethylacetate.
PDAM dissolved in ethylacetate was mixed with the deproteinized serum sample. The derivatization was carried out without addition of buffer or pH adjustment because the MMA and EMA derivatives are formed in high yield at neutral pH (17).
The time course for the formation of the MMA derivative in serum extract under these conditions is shown in Figure 1 . The reaction rate was almost constant for 5 hand leveled off after 12 h. On the basis of these results, we derivatized the samples overnight at room temperature. Figure 2 shows the formation of the MMA derivative as a function of the concentration of PDAM. Maximal fluorescence yield was obtained at a final PDAM concentration of 0.4-0.5 gIL.
We observed that the formation of PDAM derivatives of both MMA and EMA in EDTA-plasma was -30% of that in serum, as shown by the fluorescence yield. In addition, material was formed that was eluted from the ODS column as two peaks. We regarded consumption of PDAM through reaction with EDTA as a possible explanation, and tried to complex EDTA by adding ZnC12 serum, ZnC12 caused a progressive decrease in yield (Figure 3) . This finding suggests that both free EDTA and ZnC12 influence the formation of the 1-pyrenylmethyl monoesters. When assaying EDTA-plasma, we deproteinized the samples with methanol/acetonitrile so- We previously identified the PDAM derivative of MMA as 1-pyrenylmethyl methylmalonate monoester (17) . This monoester and related compounds are retained on a strong anion-exchange resin probably through interaction with the free carboxylic acid moiety, which is in anionic form at neutral pH. We therefore developed optimal conditions for the purification of derivatized serum on a SAX extraction column. After sample loading, the column was washed first with methanol and then with dilute citric acid in methanol. Figure 4 demonstrates the high efficiency of this extraction step.
HPLC. We studied the chromatographic behavior of MMA and EMA derivatives on two reversed-phase columns, C18 and C8, and on a CN column. In all systems, the retention time was highly dependent on the pH of the mobile phase, and decreasing the pH below pH 4.5 markedly increased the capacity factor. The MMA derivative was (almost) resolved from interfering peaks on an ODS column or on a C8 column when eluted with an acetonitrile gradient in ammonium formate buffer (pH 4.56). However, the MMA derivative migrated close behind a large peak, which occasionally interfered. The order of elution of the PDAM derivatives from the CN column differed from that observed with the reversedphase columns, and both the MMA and the EMA derivatives could be resolved on the CN column. One optimized system based on elution involving gradients of pH and acetomtrile content resulted in long retention times, broad peaks, low sensitivity, and occasional interference from closely eluting material. In another system, the CN column was developed isocratically at low pH (2.3), and the MMA derivative was eluted in a valley close to interfering material. Minor inaccuracies in pH adjustment or evaporation of the organic solvent from the mobile phase caused major changes in the elution proffle and affected resolution.
We then developed a system based on column-switching, where a narrow zone of the effluent from the CN column containing the MMA and EMA derivatives was directed into an ODS column. The PDAM derivatives were eluted from the first column at low pH, and the derivatives in the appropriate segment of this effluent were stacked on the ODS column, which was then eluted with a sharp tetrahydrofuran gradient, with a gradual decrease in the concentration of phosphoric acid and acetonitrile (solution A). We used tetrahydrofuran because of its low fluorescence quenching. MMA and EMA derivatives were eluted as sharp peaks clearly separated from interfering material.
To investigate the dependence of the system on the performance of the CN column, we gradually widened the zone of effluent sent to the ODS column. No material We compared the reaction kinetics of PDAM with MMA and EMA in serum extracts at various PDAM concentrations and temperatures. The kinetics for the formation of these two derivatives were identical, and the ratio between the two peaks remained constant, regardless of conditions and reaction time (data not shown). The MMA and EMA derivatives also showed identical behavior on the SAX extraction column. Parallel elution was observed when the column was developed with large volumes of methanol (>2 mL) or with dilute acid in methanol (data not shown). These data verify the use of EMA as an internal standard for the MMA assay described here.
Analytical Variables
We added MMA to serum and urine (diluted to a creatinine value of 1 mmol/L) to final concentrations of 0.125-1000 mol/L.
The standard curve was linear for MMA concentrations up to 1000 moI/L in serum and to 300 mmollmol creatinine in urine (Figure 6 ). In urine, the deviation above 300 mmollmol creatinine may be explained by consumption of PDAM in the presence of large amounts of other carboxylic acids.
The detection limit (sensitivity) of the assay is -0.02 pmoIJL in serum, corresponding to 5 fmol of MMA in the 20-ML injection volume. The sensitivity is not limited by detector noise, but is determined by the magnitude of peaks eluting in the vicinity of MMA.
For the serum measurements, the within-day and between-day imprecision (CV) was <10.9% for MMA in the range 0.12-50 moI/L. For the urine measurements, within-day imprecision was <2.5% for MMA in the range 1.86-53.20 Mmol/L ( Table 1 ). The analytical recovery of 0.5-50 mol/L MMA added to either serum or urine exceeded 85% (Table 1) .
MMA Concentrations in Serum and Plasma
We also determined MMA in 10 replicates of serum, arm-plasma were similar, whereas recovery of MMA in EDTA-plasma was low and two peaks derived from EDTA were eluted ahead of MMA (Figure 7) . The correlation between MMA measured in serum (y), heparm-plasma Serum MMA was also determined in 15 patients with cobalainin deficiency.
The results, plus their serum cobalamin and plasma homocysteine concentrations, are listed in Table 2 . The MMA concentrations (range
in most of these patients significantly exceeded the values in healthy subjects.
Discussion
Aryldiazomethanes are fluorogenic labeling reagents that react with carboxylic acids. 9-Anthryldiazo- (Figure 5) . Using a column-switching technique gave a much shorter retention time than did the serial elution of both columns, and the sample output was considerably higher because of simultaneous elution and equilibration of the columns. However, we preferred the method based on serial elution because this requires only one solvent-delivery system and no column-switching valve; moreover, columns are not subject to derangement from the pressure surge generated during column switching.
We found the present method to be reliable and adequately precise ( We developed this method for the determination of MMA in serum, but it also measures MMA in heparinplasma and in EDTA-plasma when EDTA is titrated with ZnC12. Free EDTA probably interferes with the method by consuming PDAM, but it may also affect the retention of the 1-pyrenylmethyl monoesters on the SAX columns. The compatibility of the GO-MS techniques with EDTA-containing samples has not been documented (7, 10). The option of measuring MMA in EDTA-plasma or heparin-plasma may be advantageous when only these materials are available, e.g., in research projects involving stored plasma samples. Furthermore, given that homocysteine should be measured in rapidly prepared plasma to prevent artificial increases in plasma homocysteine (25), it is useful that MMA can be determined in such samples to verify the diagnosis of cobalamin deficiency.
Both the GO-MS assays (7, 10) and the methods developed by us measure MMA in urine.
The mean value for MMA in serum from 44 healthy subjects was 0.187 moI/L ( In addition, all cobalamindeficient patients also showed a substantial increase in plasma homocysteine, emphasizing the value of simultaneous determination of both homocysteine and MMA.
In conclusion, the performance of this first liquidchromatographic assay of MMA in serum is comparable with that of the previously described GO-MS assays.
However, this assay has the advantage of simpler sample processing and can also measure MMA in EDTA-or heparin-treated plasma and urine. It represents an alternative to the established GO-MS techniques, especially in laboratories where the technician has no training in gas chromatography or mass spectrometry.
